Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6544
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry ; day:8 ; month:7 ; year:2020 ; pages:1-12
Cardiology and therapy ; (8.7.2020), 1-12
- Creator
-
Zeymer, Uwe
Lober, Christiane
Wolf, Andreas
Richard, Frank
Schäfer, Heinrich
Taggeselle, Jens
Kabitz, Hans-Joachim
Prondzinsky, Roland
Süselbeck, Tim
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40119-020-00188-1
- URN
-
urn:nbn:de:101:1-2020090618503251399214
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zeymer, Uwe
- Lober, Christiane
- Wolf, Andreas
- Richard, Frank
- Schäfer, Heinrich
- Taggeselle, Jens
- Kabitz, Hans-Joachim
- Prondzinsky, Roland
- Süselbeck, Tim
- SpringerLink (Online service)
Other Objects (12)
Initial apixaban dosing in patients with atrial fibrillation
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Clot time ratio (CTR) and treatment outcomes in Apixaban-treated atrial fibrillation patients
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial
Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES
Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial
Atrial fibrosis progression in patients with Atrial Fibrillation
Initial apixaban dosing in patients with atrial fibrillation
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Clot time ratio (CTR) and treatment outcomes in Apixaban-treated atrial fibrillation patients
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial
Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES
Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial
Atrial fibrosis progression in patients with Atrial Fibrillation
Initial apixaban dosing in patients with atrial fibrillation
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Clot time ratio (CTR) and treatment outcomes in Apixaban-treated atrial fibrillation patients
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial
Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES
Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial